Biolabex's Mauritius R&D lab open for business

By Gareth Macdonald

- Last updated on GMT

iStock/vale_t
iStock/vale_t
Biolabex has opened a manufacturing and R&D laboratory at BioPark Mauritius, a biohub in Vacoas-Phoenix south of the capital Port Louis.

The 500 sqm facility houses capacity for analytical and manufacturing services, formulation development and regulatory consulting to the pharmaceutical, nutraceutical and cosmetics sectors.

Mauritius-headquartered Biolabex describes the facility as one of its two strategic locations, with the other being its office in Paris.

CEO Marc Labiche suggested that Mauritius site would help the firm attract clients interested in the Island nation’s biodiversity.

He told us "The Mascareignes archipelago and specifically Mauritius, close to Madagascar, is one of the famous biodiversity hotspots in the word, with a large amount of endemic plants. Therefore, Biolabex, a Mauritius-based services firm saw great potential in locating its first laboratory here​."

Labiche added that "An international firm will find, with Biolabex, a unique successful combination: First, a rich source of natural active ingredients from locally grown crops, with sustainable development and fair trade.

"Secondly, a full spectrum of R&D and consulting services allowing a rational and scientific use of these local ingredients in developing new cosmetical and pharmaceutical products​."

Trade talks

In 2013, the European Parliament backed plans for a trade partnership with East African nations.

The agreement – which is currently​ being negotiated - includes provisions to increase European firms’ access to markets in Madagascar, Mauritius, Seychelles and Zimbabwe​, with pharmaceutical being among the products mentioned.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars